Table 2 Characteristics of the patients included
Case | Gender | Age | KPS | RPA | MGMT | EOR (%) | OS (months) | MMSE | Second-therapy |
|---|---|---|---|---|---|---|---|---|---|
1 | M | 69 | 70 | 5 | Met | 100 | 27.0 | 28 | Tmz |
2 | M | 70 | 70 | 5 | NoMet | 99.3 | 9.1 | 27 | Ir-Bev |
3 | F | 50 | 80 | 5 | Met | 97.9 | 66 | 26 | Ir-Bev |
4 | F | 67 | 60 | 5 | Met | 100 | 27.4 | 28 | Ir-Bev |
5 | F | 70 | 90 | 4 | Met | 100 | 40.3 | 30 | Ir-Bev |
6 | F | 44 | 100 | 3 | unMet | 100 | 23.4 | 30 | Ir-Bev |
7 | F | 67 | 90 | 5 | Met | 100 | 51.4 | 30 | No |
8 | M | 65 | 70 | 5 | Met | 100 | 3.5* | 26 | No |
9 | F | 54 | 70 | 5 | unMet | 100 | 16.8 | 26 | Ir-Bev |
10 | F | 63 | 90 | 4 | unMet | 100 | 6.1 | 30 | No |
11 | M | 69 | 80 | 5 | unMet | 100 | 33 | 26 | Ir-Bev |
12 | M | 49 | 80 | 4 | unMet | 100 | 45.4 | 28 | Ir-Bev |
13 | M | 49 | 80 | 4 | Met | 99.5 | 51.4 | 30 | Ir-Bev |
14 | M | 47 | 80 | 4 | Met | 99.4 | 16 | 25 | Ir-Bev |
15 | F | 60 | 90 | 4 | unMet | 100 | 15 | 26 | Ir-Bev |
16 | M | 58 | 60 | 5 | unMet | 100 | 23.3 | 22 | Ir-Bev |
17 | F | 57 | 70 | 5 | unMet | 99.2 | 29.5 | 25 | Ir-Bev |
18 | F | 42 | 90 | 3 | unMet | 100 | 36.9 | 28 | Ir-Bev |
19 | F | 63 | 70 | 5 | unMet | 100 | 28.1 | 19 | Ir-Bev |
20 | M | 55 | 80 | 4 | Met | 100 | 44.7 | 30 | Ir-Bev |
21 | M | 68 | 70 | 5 | unMet | 97.2 | 13.2 | 26 | No |
22 | F | 44 | 80 | 4 | unMet | 100 | 38.1 | 26 | Ir-Bev |
23 | M | 65 | 70 | 5 | unMet | 100 | 7 | 27 | No |
24 | F | 57 | 80 | 5 | unMet | 100 | 19 | 29 | Ir-Bev |
25 | M | 46 | 100 | 3 | Met | 100 | >62.2 | 30 | Tmz |
26 | M | 61 | 70 | 5 | unMet | 100 | 5.6 | 15 | No |
27 | F | 59 | 80 | 4 | Met | 100 | >59.5 | 30 | No |
28 | F | 69 | 90 | 4 | unMet | 100 | 14.4 | 28 | No |
29 | M | 62 | 80 | 4 | Met | 100 | 21.4 | 29 | No |
30 | M | 64 | 90 | 4 | Met | 100 | 9.7* | 24 | No |
31 | M | 66 | 80 | 4 | Met | 100 | 22.4 | 29 | Ir-Bev |